| Code | Display | Definition | status |
| 54 |
adenovirus, type 4 |
adenovirus vaccine, type 4, live, oral |
retired |
| 55 |
adenovirus, type 7 |
adenovirus vaccine, type 7, live, oral |
retired |
| 82 |
adenovirus, unspecified formulation |
adenovirus vaccine, unspecified formulation |
retired |
| 24 |
Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis |
Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis |
|
| 19 |
BCG |
Bacillus Calmette-Guerin vaccine |
|
| 27 |
botulinum antitoxin |
|
|
| 26 |
cholera, unspecified formulation |
cholera vaccine, unspecified formulation |
retired |
| 29 |
CMVIG |
cytomegalovirus immune globulin, intravenous |
|
| 56 |
dengue fever tetravalent |
dengue fever vaccine, tetravalent |
|
| 12 |
diphtheria antitoxin |
|
|
| 28 |
DT (pediatric) |
diphtheria and tetanus toxoids, adsorbed for pediatric use |
retired |
| 20 |
DTaP |
diphtheria, tetanus toxoids and acellular pertussis vaccine |
|
| 106 |
DTaP, 5 pertussis antigens |
diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens |
|
| 107 |
DTaP, unspecified formulation |
diphtheria, tetanus toxoids and acellular pertussis vaccine, unspecified formulation |
retired |
| 110 |
DTaP-Hep B-IPV |
DTaP-hepatitis B and poliovirus vaccine |
|
| 50 |
DTaP-Hib |
DTaP-Haemophilus influenzae type b conjugate vaccine |
retired |
| 120 |
DTaP-Hib-IPV |
diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) |
|
| 130 |
DTaP-IPV |
Diphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivated |
|
| 01 |
DTP |
diphtheria, tetanus toxoids and pertussis vaccine |
retired |
| 22 |
DTP-Hib |
DTP-Haemophilus influenzae type b conjugate vaccine |
retired |
| 102 |
DTP-Hib-Hep B |
DTP- Haemophilus influenzae type b conjugate and hepatitis b vaccine |
|
| 57 |
hantavirus |
hantavirus vaccine |
retired |
| 52 |
Hep A, adult |
hepatitis A vaccine, adult dosage |
|
| 83 |
Hep A, ped/adol, 2 dose |
hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule |
|
| 84 |
Hep A, ped/adol, 3 dose |
hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule |
retired |
| 31 |
Hep A, pediatric, unspecified formulation |
hepatitis A vaccine, pediatric dosage, unspecified formulation |
retired |
| 85 |
Hep A, unspecified formulation |
hepatitis A vaccine, unspecified formulation |
retired |
| 104 |
Hep A-Hep B |
hepatitis A and hepatitis B vaccine |
|
| 30 |
HBIG |
hepatitis B immune globulin |
|
| 08 |
Hep B, adolescent or pediatric |
hepatitis B vaccine, pediatric or pediatric/adolescent dosage |
|
| 42 |
Hep B, adolescent/high risk infant |
hepatitis B vaccine, adolescent/high risk infant dosage |
retired |
| 43 |
Hep B, adult |
hepatitis B vaccine, adult dosage |
|
| 44 |
Hep B, high-dosage, dialysis or IC |
Hepatitis B vaccine (Hep B), high-dosage, dialysis or immunocompromised patient |
|
| 45 |
Hep B, unspecified formulation |
hepatitis B vaccine, unspecified formulation |
retired |
| 58 |
Hep C |
hepatitis C vaccine |
retired |
| 59 |
Hep E |
hepatitis E vaccine |
retired |
| 60 |
herpes simplex 2 |
herpes simplex virus, type 2 vaccine |
retired |
| 46 |
Hib (PRP-D) |
Haemophilus influenzae type b vaccine, PRP-D conjugate |
retired |
| 47 |
Hib (HbOC) |
Haemophilus influenzae type b vaccine, HbOC conjugate |
retired |
| 48 |
Hib (PRP-T) |
Haemophilus influenzae type b vaccine, PRP-T conjugate |
|
| 49 |
Hib (PRP-OMP) |
Haemophilus influenzae type b vaccine, PRP-OMP conjugate |
|
| 17 |
Hib, unspecified formulation |
Haemophilus influenzae type b vaccine, conjugate unspecified formulation |
retired |
| 51 |
Hib-Hep B |
Haemophilus influenzae type b conjugate and Hepatitis B vaccine |
retired |
| 61 |
HIV |
human immunodeficiency virus vaccine |
retired |
| 118 |
HPV, bivalent |
human papilloma virus vaccine, bivalent |
retired |
| 62 |
HPV, quadrivalent |
human papilloma virus vaccine, quadrivalent |
|
| 86 |
IG |
immune globulin, intramuscular |
|
| 87 |
IGIV |
immune globulin, intravenous |
|
| 14 |
IG, unspecified formulation |
immune globulin, unspecified formulation |
retired |
| 111 |
Influenza, live, trivalent, intranasal, PF |
Influenza, live, trivalent, intranasal, preservative free |
|
| 15 |
influenza, split (incl. purified surface antigen) |
influenza virus vaccine, split virus (incl. purified surface antigen)-retired CODE |
retired |
| 16 |
influenza, whole |
influenza virus vaccine, whole virus |
retired |
| 88 |
influenza, unspecified formulation |
influenza virus vaccine, unspecified formulation |
retired |
| 123 |
influenza, H5N1-1203 |
influenza virus vaccine, H5N1, A/Vietnam/1203/2004 (national stockpile) |
retired |
| 10 |
IPV |
poliovirus vaccine, inactivated |
|
| 02 |
OPV, trivalent |
trivalent poliovirus vaccine, live, oral |
retired |
| 89 |
polio, unspecified formulation |
poliovirus vaccine, unspecified formulation |
retired |
| 39 |
Japanese encephalitis SC |
Japanese Encephalitis Vaccine SC |
retired |
| 63 |
Junin virus |
Junin virus vaccine |
retired |
| 64 |
leishmaniasis |
leishmaniasis vaccine |
retired |
| 65 |
leprosy |
leprosy vaccine |
retired |
| 66 |
Lyme disease |
Lyme disease vaccine |
retired |
| 03 |
MMR |
measles, mumps and rubella virus vaccine |
|
| 04 |
M/R |
measles and rubella virus vaccine |
retired |
| 94 |
MMRV |
measles, mumps, rubella, and varicella virus vaccine |
|
| 67 |
malaria |
malaria vaccine |
retired |
| 05 |
measles |
measles virus vaccine |
retired |
| 68 |
melanoma |
melanoma vaccine |
retired |
| 32 |
meningococcal MPSV4 |
meningococcal polysaccharide vaccine (MPSV4) |
retired |
| 103 |
meningococcal C conjugate |
meningococcal C conjugate vaccine |
retired |
| 114 |
meningococcal MCV4P |
meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P) |
|
| 108 |
meningococcal ACWY, unspecified formulation |
meningococcal ACWY vaccine, unspecified formulation |
retired |
| 07 |
mumps |
mumps virus vaccine |
retired |
| 69 |
parainfluenza-3 |
parainfluenza-3 virus vaccine |
retired |
| 11 |
pertussis |
pertussis vaccine |
retired |
| 23 |
plague |
plague vaccine |
retired |
| 33 |
pneumococcal polysaccharide PPV23 |
pneumococcal polysaccharide vaccine, 23 valent |
|
| 100 |
pneumococcal conjugate PCV 7 |
pneumococcal conjugate vaccine, 7 valent |
retired |
| 109 |
pneumococcal, unspecified formulation |
pneumococcal vaccine, unspecified formulation |
retired |
| 70 |
Q fever |
Q fever vaccine |
retired |
| 18 |
rabies, intramuscular injection |
rabies vaccine, for intramuscular injection RETIRED CODE |
retired |
| 40 |
rabies, intradermal injection |
rabies vaccine, for intradermal injection |
retired |
| 90 |
rabies, unspecified formulation |
rabies vaccine, unspecified formulation |
retired |
| 72 |
rheumatic fever |
rheumatic fever vaccine |
retired |
| 73 |
Rift Valley fever |
Rift Valley fever vaccine |
retired |
| 34 |
RIG |
rabies immune globulin |
|
| 119 |
rotavirus, monovalent |
rotavirus, live, monovalent vaccine |
|
| 122 |
rotavirus, unspecified formulation |
rotavirus vaccine, unspecified formulation |
retired |
| 116 |
rotavirus, pentavalent |
rotavirus, live, pentavalent vaccine |
|
| 74 |
rotavirus, tetravalent |
rotavirus, live, tetravalent vaccine |
retired |
| 71 |
RSV-IGIV |
respiratory syncytial virus immune globulin, intravenous |
retired |
| 93 |
RSV-MAb |
respiratory syncytial virus monoclonal antibody (palivizumab), intramuscular |
|
| 06 |
rubella |
rubella virus vaccine |
retired |
| 38 |
rubella/mumps |
rubella and mumps virus vaccine |
retired |
| 76 |
Staphylococcus bacterio lysate |
Staphylococcus bacteriophage lysate |
retired |
| 113 |
Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed |
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (5 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) |
|
| 09 |
Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed |
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) |
|
| 115 |
Tdap |
tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed |
|
| 35 |
tetanus toxoid, adsorbed |
|
retired |
| 112 |
tetanus toxoid, unspecified formulation |
|
retired |
| 77 |
Tick-borne encephalitis vaccine (non-US) |
|
|
| 13 |
TIG |
tetanus immune globulin |
|
| 95 |
TST-OT tine test |
tuberculin skin test; old tuberculin, multipuncture device |
retired |
| 96 |
TST-PPD intradermal |
tuberculin skin test; purified protein derivative solution, intradermal |
retired |
| 97 |
TST-PPD tine test |
tuberculin skin test; purified protein derivative, multipuncture device |
retired |
| 98 |
TST, unspecified formulation |
tuberculin skin test; unspecified formulation |
retired |
| 78 |
tularemia vaccine |
|
retired |
| 91 |
typhoid, unspecified formulation |
typhoid vaccine, unspecified formulation |
retired |
| 25 |
typhoid, oral |
typhoid vaccine, live, oral |
|
| 41 |
typhoid, parenteral |
typhoid vaccine, parenteral, other than acetone-killed, dried |
retired |
| 53 |
typhoid, parenteral, AKD (U.S. military) |
typhoid vaccine, parenteral, acetone-killed, dried (U.S. military) |
retired |
| 101 |
typhoid, ViCPs |
typhoid Vi capsular polysaccharide vaccine |
|
| 75 |
Vaccinia (smallpox, monkeypox), live |
Vaccinia (smallpox, monkeypox) vaccine, live |
|
| 105 |
vaccinia (smallpox) diluted |
vaccinia (smallpox) vaccine, diluted |
retired |
| 79 |
vaccinia immune globulin |
|
|
| 21 |
varicella |
varicella virus vaccine |
|
| 81 |
VEE, inactivated |
Venezuelan equine encephalitis, inactivated |
retired |
| 80 |
VEE, live |
Venezuelan equine encephalitis, live, attenuated |
retired |
| 92 |
VEE, unspecified formulation |
Venezuelan equine encephalitis vaccine, unspecified formulation |
retired |
| 36 |
VZIG |
varicella zoster immune globulin |
|
| 117 |
VZIG (IND) |
varicella zoster immune globulin (Investigational New Drug) |
retired |
| 37 |
yellow fever live |
yellow fever vaccine live |
|
| 121 |
zoster live |
zoster vaccine, live |
retired |
| 998 |
no vaccine administered |
|
retired |
| 999 |
unknown |
unknown vaccine or immune globulin |
retired |
| 99 |
RESERVED - do not use |
|
retired |
| 133 |
Pneumococcal conjugate PCV 13 |
pneumococcal conjugate vaccine, 13 valent |
|
| 134 |
Japanese Encephalitis IM |
Japanese Encephalitis vaccine for intramuscular administration |
|
| 137 |
HPV, unspecified formulation |
|
retired |
| 136 |
Meningococcal MCV4O |
meningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O) |
|
| 135 |
Influenza, high-dose, trivalent, PF |
Influenza, high-dose, split virus, trivalent, injectable, preservative free |
|
| 131 |
typhus, historical |
Historical record of a typhus vaccination |
retired |
| 132 |
DTaP-IPV-HIB-HEP B, historical |
Historical diphtheria and tetanus toxoids and acellular pertussis, poliovirus, Haemophilus b conjugate and hepatitis B (recombinant) vaccine. |
retired |
| 128 |
Novel Influenza-H1N1-09, all formulations |
Novel influenza-H1N1-09, all formulations |
retired |
| 125 |
Novel Influenza-H1N1-09, nasal |
Novel Influenza-H1N1-09, live virus for nasal administration |
retired |
| 126 |
Novel influenza-H1N1-09, preservative-free |
Novel influenza-H1N1-09, preservative-free, injectable |
retired |
| 127 |
Novel influenza-H1N1-09 |
Novel influenza-H1N1-09, injectable |
retired |
| 138 |
Td (adult) |
tetanus and diphtheria toxoids, not adsorbed, for adult use |
retired |
| 139 |
Td(adult) unspecified formulation |
|
retired |
| 140 |
Influenza, split virus, trivalent, PF |
Influenza, split virus, trivalent, injectable, preservative free |
|
| 129 |
Japanese Encephalitis, unspecified formulation |
Japanese Encephalitis vaccine, unspecified formulation |
retired |
| 141 |
Influenza, split virus, trivalent, preservative |
Influenza, split virus, trivalent, injectable, contains preservative |
|
| 142 |
tetanus toxoid, not adsorbed |
|
retired |
| 143 |
Adenovirus types 4 and 7 |
Adenovirus, type 4 and type 7, live, oral |
|
| 144 |
influenza, seasonal, intradermal, preservative free |
seasonal influenza, intradermal, preservative free |
retired |
| 145 |
RSV-MAb (new) |
respiratory syncytial virus monoclonal antibody (motavizumab), intramuscular |
retired |
| 146 |
DTaP,IPV,Hib,HepB |
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine. |
|
| 147 |
meningococcal MCV4, unspecified formulation |
Meningococcal, MCV4, unspecified conjugate formulation(groups A, C, Y and W-135) |
retired |
| 148 |
Meningococcal C/Y-HIB PRP |
Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine |
retired |
| 149 |
Influenza, live, quadrivalent, intranasal |
|
|
| 150 |
Influenza, split virus, quadrivalent, PF |
Influenza, split virus, quadrivalent, injectable, preservative free |
|
| 151 |
influenza nasal, unspecified formulation |
|
retired |
| 152 |
Pneumococcal Conjugate, unspecified formulation |
|
retired |
| 153 |
Influenza, MDCK, trivalent, PF |
Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, preservative free |
|
| 154 |
Hep A, IG |
Hepatitis A immune globulin |
retired |
| 155 |
Influenza, recombinant, trivalent, PF |
Influenza, recombinant, trivalent, injectable, preservative free |
|
| 156 |
Rho(D)-IG |
Rho(D) Immune globulin- IV or IM |
|
| 157 |
Rho(D) -IG IM |
Rho(D) Immune globulin - IM |
|
| 158 |
Influenza, split virus, quadrivalent, preservative |
Influenza, split virus, quadrivalent, injectable, contains preservative |
|
| 159 |
Rho(D) - Unspecified formulation |
Rho(D) Unspecified formulation |
retired |
| 160 |
Influenza A monovalent (H5N1), ADJUVANTED-2013 |
Influenza A monovalent (H5N1), adjuvanted, National stockpile 2013 |
|
| 801 |
AS03 Adjuvant |
|
|
| 161 |
Influenza, injectable,quadrivalent, preservative free, pediatric |
|
|
| 162 |
meningococcal B, recombinant |
meningococcal B vaccine, fully recombinant |
|
| 163 |
meningococcal B, OMV |
meningococcal B vaccine, recombinant, OMV, adjuvanted |
|
| 164 |
meningococcal B, unspecified |
meningococcal B, unspecified formulation |
retired |
| 165 |
HPV9 |
Human Papillomavirus 9-valent vaccine |
|
| 166 |
influenza, intradermal, quadrivalent, preservative free |
influenza, intradermal, quadrivalent, preservative free, injectable |
retired |
| 167 |
meningococcal, unknown serogroups |
meningococcal vaccine of unknown formulation and unknown serogroups |
retired |
| 168 |
Influenza, adjuvanted, trivalent, PF |
Influenza, adjuvanted, inactivated, trivalent, injectable, preservative free |
|
| 169 |
Hep A, live attenuated |
Hep A, live attenuated-IM |
|
| 170 |
DTAP/IPV/HIB - non-US |
non-US diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) |
|
| 171 |
Influenza, MDCK, quadrivalent, PF |
Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, preservative free |
|
| 172 |
cholera, WC-rBS |
|
|
| 173 |
cholera, BivWC |
|
|
| 174 |
cholera, live attenuated |
|
|
| 175 |
Rabies - IM Diploid cell culture |
Human Rabies vaccine from human diploid cell culture |
|
| 176 |
Rabies - IM fibroblast culture |
Human rabies vaccine from Chicken fibroblast culture |
|
| 177 |
PCV10 |
pneumococcal conjugate vaccine, 10 valent |
|
| 178 |
OPV bivalent |
Non-US bivalent oral polio vaccine (types 1 and 3) |
|
| 179 |
OPV ,monovalent, unspecified |
Non-US monovalent oral polio vaccine, unspecified formulation |
|
| 180 |
tetanus immune globulin |
|
retired |
| 181 |
anthrax immune globulin |
|
|
| 182 |
OPV, Unspecified |
Oral Polio Vaccine, Unspecified formulation |
retired |
| 183 |
Yellow fever vaccine live - alt |
Yellow fever vaccine live - alternative formulation for vaccine shortage |
|
| 184 |
Yellow fever, unspecified |
Yellow fever vaccine, unspecified formulation |
retired |
| 185 |
Influenza, recombinant, quadrivalent, PF |
Influenza, recombinant, quadrivalent, injectable, preservative free |
|
| 186 |
Influenza, MDCK, quadrivalent, preservative |
Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, contains preservative |
|
| 187 |
zoster recombinant |
zoster vaccine recombinant |
|
| 188 |
zoster, unspecified formulation |
zoster vaccine, unspecified formulation |
retired |
| 189 |
HepB-CpG |
Hepatitis B vaccine (recombinant), CpG adjuvanted |
|
| 190 |
Typhoid conjugate vaccine (TCV) |
Typhoid conjugate vaccine (non-US) |
|
| 191 |
meningococcal A polysaccharide (non-US) |
meningococcal A polysaccharide vaccine (non-US) |
|
| 192 |
meningococcal AC polysaccharide (non-US) |
meningococcal AC polysaccharide vaccine (non-US) |
|
| 193 |
Hep A-Hep B, pediatric/adolescent |
hepatitis A and hepatitis B vaccine, pediatric/adolescent (non-US) |
|
| 194 |
Influenza, Southern Hemisphere |
influenza, Southern Hemisphere, unspecified formulation |
retired |
| 195 |
DT, IPV adsorbed |
Diphtheria, Tetanus, Poliomyelitis adsorbed |
|
| 196 |
Td, adsorbed, preservative free, adult use, Lf unspecified |
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecified |
|
| 197 |
Influenza, high-dose, quadrivalent, PF |
Influenza, high-dose, split virus, quadrivalent, injectable, preservative free |
|
| 200 |
influenza, Southern Hemisphere, pediatric, preservative free |
influenza, seasonal, Southern Hemisphere, quadrivalent, pediatric 0.25mL dose, preservative free |
|
| 201 |
Influenza, Southern Hemisphere, quadrivalent, PF |
Influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5 mL dose, preservative free |
|
| 202 |
influenza, Southern Hemisphere, quadrivalent, with preservative |
influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, with preservative |
|
| 198 |
DTP-hepB-Hib Pentavalent Non-US |
Diphtheria, pertussis, tetanus, hepatitis B, Haemophilus Influenza Type b, (Pentavalent) |
|
| 203 |
meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) |
meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine 0.5mL dose, preservative free |
|
| 205 |
Influenza, adjuvanted, quadrivalent, PF |
Influenza, adjuvanted, inactivated, quadrivalent, injectable, preservative free |
|
| 206 |
Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection |
Vaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injection |
|
| 207 |
COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose |
retired |
| 208 |
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose |
retired |
| 213 |
SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED |
|
retired |
| 210 |
COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL |
SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL |
|
| 212 |
COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL |
SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL |
retired |
| 204 |
Ebola Zaire vaccine, live, recombinant, 1mL dose |
|
|
| 214 |
Ebola, unspecified |
|
retired |
| 211 |
COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL |
SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose |
retired |
| 500 |
COVID-19 Non-US Vaccine, UNSPECIFIED |
SARS-COV-2 (COVID-19) Non-US Vaccine, UNSPECIFIED |
|
| 501 |
COVID-19 IV Non-US Vaccine (QAZCOVID-IN) |
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN) |
|
| 502 |
COVID-19 IV Non-US Vaccine (COVAXIN) |
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN) |
|
| 503 |
COVID-19 LAV Non-US Vaccine (COVIVAC) |
SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC) |
|
| 504 |
COVID-19 VVnr Non-US Vaccine (Sputnik Light) |
SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light) |
|
| 505 |
COVID-19 VVnr Non-US Vaccine (Sputnik V) |
SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V) |
|
| 506 |
COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology |
SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology |
|
| 507 |
COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) |
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences) |
|
| 508 |
COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) |
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention) |
|
| 509 |
COVID-19 PS Non-US Vaccine (EpiVacCorona) |
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona) |
|
| 510 |
COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) |
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm) |
|
| 511 |
COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) |
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac) |
|
| 215 |
Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF |
Pneumococcal conjugate vaccine 15-valent (PCV15), polysaccharide CRM197 conjugate, adjuvant, preservative free |
|
| 216 |
Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF |
Pneumococcal conjugate vaccine 20-valent (PCV20), polysaccharide CRM197 conjugate, adjuvant, preservative free |
|
| 219 |
COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation |
retired |
| 217 |
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation |
retired |
| 218 |
COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation |
retired |
| 220 |
HepB recombinant, 3-antigen, Al(OH)3 |
Hepatitis B vaccine (recombinant), 3-antigen, Al(OH)3 adjuvanted |
retired |
| 221 |
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose |
retired |
| 222 |
Tick-borne encephalitis, unspecified |
Tick-borne encephalitis vaccine, unspecified |
retired |
| 223 |
Tick-borne encephalitis, inactivated, PF, 0.25mL |
Tick-borne encephalitis vaccine, inactivated, preservative free, 0.25mL dose |
|
| 224 |
Tick-borne encephalitis, inactivated, PF, 0.5mL |
Tick-borne encephalitis vaccine, inactivated, preservative free, 0.5mL dose |
|
| 225 |
COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL |
SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 5mcg/0.5mL dose |
retired |
| 226 |
COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL |
SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 10mcg/0.5mL dose |
retired |
| 512 |
SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) |
SARS-COV-2 COVID-19 Virus Like Particle (VLP) Non-US Vaccine Product (Medicago, Covifenz) |
|
| 513 |
SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) |
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom, Zifivax) |
|
| 514 |
SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) |
SARS-COV-2 COVID-19 DNA Non-US Vaccine Product (Zydus Cadila, ZyCoV-D) |
|
| 515 |
SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) |
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Medigen, MVC-COV1901) |
|
| 516 |
COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) |
SARS-COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) |
|
| 517 |
SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) |
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Biological E Limited, Corbevax) |
|
| 227 |
COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 50 mcg/0.5 mL dose |
retired |
| 228 |
COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose |
retired |
| 229 |
COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose |
retired |
| 301 |
COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation |
retired |
| 300 |
COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation |
retired |
| 230 |
COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose |
retired |
| 518 |
COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) |
SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) |
|
| 519 |
COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna |
SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna |
|
| 520 |
COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech |
SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech |
|
| 521 |
COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK |
SARS-COV-2 (COVID-19) vaccine SP, protein-based, adjuvanted, B.1.351 strain (VidPrevtyn Beta), Sanofi-GSK |
|
| 231 |
influenza, Southern Hemisphere, high-dose, quadrivalent |
influenza, seasonal, Southern Hemisphere, high-dose, quadrivalent, 0.7mL dose, preservative free |
|
| 303 |
RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF |
Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free |
|
| 304 |
Respiratory syncytial virus (RSV), unspecified |
|
retired |
| 305 |
RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF |
Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free |
|
| 306 |
RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months |
Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months |
|
| 307 |
RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months |
Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months |
|
| 313 |
COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL |
SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose |
|
| 308 |
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose |
retired |
| 309 |
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose |
|
| 310 |
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose |
|
| 312 |
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose |
|
| 311 |
COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose |
|
| 315 |
Respiratory syncytial virus (RSV) MAB, unspecified |
Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified |
retired |
| 314 |
Respiratory syncytial virus (RSV) vaccine, unspecified |
|
retired |
| 316 |
Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF |
Meningococcal polysaccharide (groups A, C, Y, W) tetanus toxoid conjugate, meningococcal B recombinant vaccine, 0.5mL, preservative free |
|
| 317 |
Chikungunya live attenuated vaccine, 0.5 mL, PF |
Chikungunya, live attenuated vaccine, 0.5 mL, preservative free |
|
| 318 |
Anthrax, post-exposure prophylaxis |
Anthrax vaccine, adsorbed, adjuvanted, post-exposure prophylaxis |
|
| 319 |
Anthrax vaccine, unspecified |
|
retired |
| 320 |
Influenza, MDCK, trivalent, preservative |
Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, contains preservative |
|
| 321 |
Influenza-avian, H5N8, monovalent, PF |
Influenza-avian, H5N8, viral-vector, monovalent, injectable, preservative free |
|
| 322 |
Influenza-avian, H5N8, monovalent, preservative |
Influenza-avian, H5N8, viral-vector, monovalent, injectable, contains preservative |
|
| 324 |
Poliovirus, inactivated, fractional-dose (fIPV) |
|
|
| 323 |
Influenza-avian, H5, unspecified formulation |
|
retired |
| 326 |
RSV, mRNA, injectable, PF |
Respiratory syncytial virus (RSV), mRNA, injectable, preservative free |
|
| 327 |
Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF |
Pneumococcal conjugate vaccine, 21 valent (PCV21), polysaccharide CRM197 conjugate, preservative free |
|
| 328 |
Meningococcal oligosaccharide (MenACWY), (MenB), PF |
Meningococcal oligosaccharide conjugated (groups A, C, W, Y) and group B, 0.5 mL, preservative free |
|
| 329 |
Chikungunya, VLP, recombinant, 0.8 mL, PF |
Chikungunya, virus-like particle (VLP), recombinant vaccine, 0.8 mL, preservative free |
|
| 330 |
Dengue fever, unspecified |
Dengue fever, unspecified formulation |
retired |
| 331 |
Influenza, Southern Hemisphere, trivalent, PF |
Influenza, seasonal, Southern Hemisphere, trivalent, 0.5 mL dose, preservative free |
|
| 325 |
Vaccinia (smallpox, monkeypox), unspecified |
|
retired |
| 332 |
RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF |
Respiratory syncytial virus (RSV), monoclonal antibody, IgG1κ, (clesrovimab-cfor), 0.7 mL, neonate and infant, preservative free |
|
| 333 |
Influenza, live, trivalent, intranasal, self/caregiver admin, PF |
Influenza, live, trivalent, intranasal, self or caregiver administered, preservative free |
|
| 334 |
COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2 mL dose |
|
| 337 |
Influenza, Southern Hemisphere, high-dose, trivalent, PF |
Influenza, Southern Hemisphere, high-dose, split virus, trivalent, 0.5 mL, injectable, preservative free |
|
| 302 |
COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose |
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation |
retired |